Clinical trial NCT00093405 (phase 2, status: completed)
Conditions: kidney cancer
ICD codes: D17.71, D30.00, D30.01, D30.02, D41.00, D41.01, D41.02
Drugs: tanespimycin
SMILES: [H]/C1=C([H])/[C@]([H])(OC)[C@@]([H])(OC(O)=N)C(C)=C([H])[C@]([H])(C)[C@@]([H])(O)[C@]([H])(C[C@]([H])(C)CC2=C(NCC=C)C(=O)C=C(N=C(O)\C(C)=C\1/[H])C2=O)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed renal cell carcinoma

               -  Papillary OR clear cell histology

                    -  If other histologies are present, clear cell or papillary must be
                       predominant

               -  Metastatic disease

          -  Measurable disease

               -  At least 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques
                  OR ≥ 10 mm by spiral CT scan

          -  No brain metastases unless previously treated with radiotherapy or surgery AND
             asymptomatic with no active brain metastases detectable by CT scan or MRI for ≥ 6
             months

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  Karnofsky 70-100%

        Life expectancy

          -  Not specified

        Hematopoietic

          -  WBC ≥ 3,000/mm^3

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

        Hepatic

          -  AST and ALT ≤ 1.5 times upper limit of normal (ULN)

          -  Bilirubin ≤ 1.5 times ULN

        Renal

          -  Creatinine ≤ 2.0 times ULN

        Cardiovascular

          -  No symptomatic congestive heart failure

          -  No unstable angina pectoris

          -  No cardiac arrhythmia

          -  No severe valvular disease

        Pulmonary

          -  No severe debilitating pulmonary disease

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No allergy to egg or egg products

          -  No history of allergic reactions attributed to compounds of similar chemical or
             biological composition to 17-N-allylamino-17-demethoxygeldanamycin (17-AAG)

          -  No active or ongoing infection requiring IV antibiotics

          -  No psychiatric illness or social situation that would preclude study compliance

          -  No other uncontrolled illness

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No more than 1 prior cytokine-based regimen

          -  No concurrent biologic therapy

        Chemotherapy

          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  More than 4 weeks since prior radiotherapy

          -  No concurrent radiotherapy

        Surgery

          -  More than 4 weeks since prior major surgery

        Other

          -  Recovered from prior therapy

          -  No more than 1 prior non-cytokine-based regimen

          -  No other prior systemic treatment regimens

          -  No other concurrent cytotoxic therapy

          -  No other concurrent anticancer therapy

          -  No other concurrent investigational agents